Clay Siegall has been a revered individual in the cancer treatment field since the establishment of Seattle Genetics. He has been working with leading researcher at the company to come up with targeted therapies and drugs for cancer treatment. Seattle Genetics was established as a small biotechnology firm and has been growing into a top player in cancer research over the years. Siegall has been striving to develop customized treatments that can be used in curing individual cancer patients.
Dr. Siegall started considering the development of alternative cancer treatments after noticing the adverse effect of the chemotherapy on a family member who had cancer. He completed his undergraduate degree in from the University of Maryland. The operations of Seattle Genetics are currently funded by selling its FDA-approved drugs both locally and internationally. The company has also been raising funds through private and public offerings, and its IPO was in 2001. Investors played a great role in getting the company off the ground.
Clay is a professional geneticist who came to the limelight after the founding of Seattle Genetics. He was admitted at the George Washington University where he got his Ph.D. in Genetics. As from 1988 to 1991, Siegall worked as a research of the National Institute of Health and the National Cancer Institute, which are government owned organization. He was then offered a position to serve Bristol-Myers Squibb Pharmaceutical Research Institute and stayed at the company until 1997.
By 1998, Dr. Clay Siegall had acquired sufficient experience in the industry, and he decided to establish Seattle Genetics. He is the CEO of the firm and has been leading it in developing excellent ADCs that can act as an alternative to chemotherapy. Clay is also the chairman of Seattle Genetic’s board of directors. He has assisted the firm in generating over $675 million by using the private and public funding programs. In 2011, the company managed to secure its first FDA approval to sell ADCETRIS, which is a form of ADC. Seattle Genetic has managed to develop more than 20 ADCs that are sold in different parts of the globe. The firm has currently partnered with Takeda Pharmaceutical Company, Bayer, and Genentech.